[1]郑卓玲,黄 民,李嘉丽.麻醉药物及其辅助药物基因组学的研究进展[J].中国药理学通报,2018,(08):1049-1052.[doi:10.3969/j.issn.1001-1978.2018.08.004]
 ZHENG Zhuo-ling,HUANG Min,LI Jia-li.Advances in research on pharmacogenomics of anesthetics and their adjuvants[J].Chinese Pharmacological Bulletin,2018,(08):1049-1052.[doi:10.3969/j.issn.1001-1978.2018.08.004]





Advances in research on pharmacogenomics of anesthetics and their adjuvants
郑卓玲黄 民李嘉丽
中山大学药学院临床药理研究所,广东 广州 510080
ZHENG Zhuo-ling HUANG Min LI Jia-li
Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510080,China
麻醉药 药物基因组学 遗传 个体化用药 代谢酶 丙泊酚
anesthetics pharmacogenomics genetic personalized medicine metabolic enzyme propofol
R-05; R394.6; R971.2; R977.3
Anesthetics and its adjuvant drugs are essential for surgery, but their drug reactions have significant individual difference in the clinical routine treatment program.Genetic polymorphism is an important influencing factor of individual differences in the pharmacokinetics and pharmacodynamics of drugs.This paper presents an overview of the research progress of pharmacogenomics of anesthetics and their adjuvant drugs at home and abroad.


[1] 陈长仁, 何发忠, 周宏灏,等.精准医学的基础研究与临床转化[J].中国药理学通报, 2015,31(12): 1629-32. [1] Chen C R, He F Z, Zhou H H,et al.Basic research and clinical translation of precision medicine [J].Chin Pharmacol Bull, 2015,31(12): 1629-32.
[2] Kaymak C, Karahalil B, Ozcan N N,et al.Association between GSTP1 gene polymorphism and serum alpha-GST concentrations undergoing sevoflurane anaesthesia[J].Eur J Anaesthesiol, 2008, 25(3): 193-9.
[3] Mikstacki A, Skrzypczak-Zielinska M, Zakerska-Banaszak O,et al.Impact of CYP2E1, GSTA1 and GSTP1 gene variants on serum alpha glutathione S-transferase level in patients undergoing anaesthesia[J].BMC Med Genet, 2016, 17(1): 9-14.
[4] Nishiyama T, Ikeda M, Iwata N,et al.Haplotype association between GABAA receptor gamma2 subunit gene(GABRG2)and methamphetamine use disorder[J].Pharmacogenomics J, 2005, 5(2): 89-95.
[5] Park C S, Park H J, Kim K N,et al.The influence of GABAAγ2 genetic polymorphism on the emergence agitation induced by sevoflurane[J].Korean J Anesthesiol, 2008, 55(2): 139-44.
[6] Liem E B, Lin C M, Suleman M I,et al.Anesthetic requirement is increased in redheads[J].Anesthesiology, 2004, 101(2): 279-83.
[7] Mulholland C V, Somogyi A A, Barratt D T,et al.Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia[J].J Mol Neurosci, 2014, 52(4): 497-506.
[8] 田丹丹.UGT1A9多态性对丙泊酚靶控输注药效学及单次注射药动学的影响[D].郑州:郑州大学,2012.
[8] Tian D D.Association of UGT1A9 gene polymorphisms with propofol pharmacodynamics of target-controlled infusion and pharmacokinetics of single injection[D].Zhengzhou: Zhengzhou University,2012.
[9] Iohom G, Ni Chonghaile M, O'Brien J K,et al.An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia[J].Eur J Anaesthesiol, 2007, 24(11): 912-9.
[10] Loryan I, Lindqvist M, Johansson I,et al.Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia[J].Eur J Clin Pharmacol, 2012, 68(4): 397-406.
[11] Takahashi H, Maruo Y, Mori A,et al.Effect of D256N and Y483D on propofol glucuronidation by human uridine 5'-diphosphate glucuronosyltransferase(UGT1A9)[J].Basic Clin Pharmacol, 2008, 103(2): 131-6.
[12] Khan M S, Zetterlund E, Gréen H,et al.Pharmacogenetics, plasma concentrations, clinical signs and eeg during propofol treatment[J].Basic Clin Pharmacol, 2014, 115(6): 565-70.
[13] Mastrogianni O, Gbandi E, Orphanidis A,et al.Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece[J].Drug Metab Pharmacok, 2014, 29(2): 215-8.
[14] Eugene A R.CYP2B6 genotype guided dosing of propofol anesthesia in the elderly based on nonparametric population pharmacokinetic modeling and simulations[J].Int J Clin Pharmacol Toxicol, 2017, 6(1): 242-9.
[15] Zhong Q, Chen X, Zhao Y,et al.Association of polymorphisms in pharmacogenetic candidate genes with propofol susceptibility[J].Sci Rep-UK, 2017, 7(1): 3343.
[16] Li Y, Jackson K A, Slon B,et al.CYP2B6*6 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects[J].Br J Clin Pharmacol, 2015, 80(2): 276-84.
[17] Lesley K, Rao L K, Alicia M, et al.Role of cytochrome P450 2B6 polymorphisms in ketamine metabolism and clearance[J].Anesthesiology, 2016, 125(6): 1103-12.
[18] Aroke E N, Crawford S L, Dungan J R.Pharmacogenetics of ketamine-induced emergence phenomena: a pilot study[J].Nurs Res, 2017, 66(2): 105-14.
[19] Liem E B, Joiner T V, Tsueda K, et al.Increased sensitivity to thermal pain and reduced subcutaneous lidocaine efficacy in redheads[J].Anesthesiology, 2005, 102(3): 509-14.
[20] Mahmoud S, Thorsell A, Sommer W H, et al.Pharmacological consequence of the A118G mu opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca2+ channels in humanized mouse sensory neurons[J].Anesthesiology, 2011, 115(5): 1054-62.
[21] Kosek E, Jensen K B, Lonsdorf T B,et al.Genetic variation in the serotonin transporter gene(5-HTTLPR, rs25531)influences the analgesic response to the short acting opioid remifentanil in humans[J].Mol Pain, 2009, 5: 37.
[22] Hodges L M, Markova S M, Chinn L W,et al.Very important pharmacogene summary[J].Pharmacogenet Genom, 2011, 21(3): 152-61.
[23] Kirchheiner J, Meineke I, Freytag G,et al.Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2[J].Clin Pharmacol Ther, 2002, 72(1): 62-75.
[24] Delacour H, Lushchekina S, Mabboux I,et al.Characterization of a novel BCHE "silent" allele: point mutation(p.Val204Asp)causes loss of activity and prolonged apnea with suxamethonium[J].PLoS One, 2014, 9(7):e101552.
[25] Mei Y, Wang S, Li Y,et al.Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients[J].J Clin Pharmacol, 2015, 55(3): 261-8.


 LIANG Han bing,SHAO Dong hua,HANG Li hua,et al.Construction and interpretation of the physical model of concentration effect[J].Chinese Pharmacological Bulletin,2012,(08):1624.
[2]张月丽,周宏灏,张 伟.维生素的药物基因组学研究进展[J].中国药理学通报,2014,(11):1503.
 ZHANG Yue-li,ZHOU Hong-hao,ZHANG Wei.Advance in research on pharmacogenomics of vitamin[J].Chinese Pharmacological Bulletin,2014,(08):1503.
 CHEN Zhang-ren,HE Fa-zhong,ZHOU Hong-hao,et al.Basic research and clinical translation of precision medicine[J].Chinese Pharmacological Bulletin,2015,(08):1629.[doi:10.3969/j.issn.1001.1978.2015.12.001]


基金项目:国家重点研发计划项目(No 2017YFC0909303, 22016 YFC0905001); “十二五”国家科技重大专项资助项目(No 2012ZX09506001-004); 广东省重点实验室建设项目(No 2011A060901014); 广东省重大科技专项(No 2011A080300001, 2012A080202013)
作者简介:郑卓玲(1993-),女,硕士生,研究方向:药代动力学与药物基因组学,Tel:020-87331409,E-mail: zhengzhl3@mail2.sysu.edu.cn;
更新日期/Last Update: 2018-07-26